Regulation of High-fat Diet-induced Liver Fibrosis by SOCS1 Expression in Hepatic Stellate Cells.

[1]  I. Mederacke,et al.  An inducible model for genetic manipulation and fate-tracing of PDGFRβ-expressing fibrogenic cells in the liver , 2023, Scientific reports.

[2]  P. Subramanian,et al.  Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease , 2023, Cellular and molecular gastroenterology and hepatology.

[3]  J. Lazarus,et al.  Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties. , 2023, Journal of hepatology.

[4]  R. Schwabe,et al.  Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis , 2022, Nature.

[5]  R. Kandhi,et al.  An improved method for isolation and flow cytometric characterization of intrahepatic leukocytes from fatty and fibrotic liver tissues , 2022, Anatomical record.

[6]  S. L. Friedman,et al.  Hepatic Stellate Cell-Immune Interactions in NASH , 2022, Frontiers in Endocrinology.

[7]  S. Friedman,et al.  Hepatic fibrosis 2022: Unmet needs and a blueprint for the future , 2021, Hepatology.

[8]  H. Guillou,et al.  New targets for NAFLD , 2021, JHEP reports : innovation in hepatology.

[9]  S. Friedman,et al.  Mechanisms and disease consequences of nonalcoholic fatty liver disease , 2021, Cell.

[10]  D. H. Ipsen,et al.  Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis—Roles as Putative Treatment Targets? , 2021, Biomedicines.

[11]  D. Brenner,et al.  Heterogeneity of HSCs in a Mouse Model of NASH , 2021, Hepatology.

[12]  B. Copple,et al.  Liver fibrosis is driven by protease‐activated receptor‐1 expressed by hepatic stellate cells in experimental chronic liver injury , 2020, Research and practice in thrombosis and haemostasis.

[13]  Y. Koyama,et al.  Identification of Lineage-specific Transcription Factors That Prevent Activation of Hepatic Stellate Cells and Promote Fibrosis Resolution. , 2020, Gastroenterology.

[14]  D. Bobbala,et al.  Essential role of suppressor of cytokine signaling 1 (SOCS1) in hepatocytes and macrophages in the regulation of liver fibrosis. , 2019, Cytokine.

[15]  C. Meyer,et al.  TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019 , 2019, Cells.

[16]  B. Fuchs,et al.  Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis , 2018, Scientific Reports.

[17]  S. Friedman,et al.  Hepatic stellate cells as key target in liver fibrosis. , 2017, Advanced drug delivery reviews.

[18]  F. Tacke.  Targeting hepatic macrophages to treat liver diseases. , 2017, Journal of hepatology.

[19]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[20]  M. Safran,et al.  Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation , 2017, PloS one.

[21]  F. Tacke,et al.  Liver macrophages in tissue homeostasis and disease , 2017, Nature Reviews Immunology.

[22]  Li-Rong Yu,et al.  Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway* , 2017, The Journal of Biological Chemistry.

[23]  A. Diehl,et al.  Pathogenesis of Nonalcoholic Steatohepatitis. , 2016, Gastroenterology.

[24]  D. Bobbala,et al.  Negative regulation of the hepatic fibrogenic response by suppressor of cytokine signaling 1. , 2016, Cytokine.

[25]  D. Torres,et al.  Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis , 2015, Hepatology.

[26]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[27]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[28]  M. Yeganeh,et al.  Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma , 2015, Oncogene.

[29]  S. Friedman,et al.  β-PDGF Receptor Expressed by Hepatic Stellate Cells Regulates Fibrosis in Murine Liver Injury, but Not Carcinogenesis , 2015, Journal of hepatology.

[30]  L. Rönnstrand,et al.  SOCS proteins in regulation of receptor tyrosine kinase signaling , 2014, Cellular and Molecular Life Sciences.

[31]  E. Casanova,et al.  O147 HEPATIC STELLATE CELLS ARE THE MAJOR SOURCE OF COLLAGEN IN MURINE MODELS OF LIVER FIBROSIS , 2014 .

[32]  R. Schwabe,et al.  Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.

[33]  A. Diehl,et al.  NAFLD, NASH and liver cancer , 2013, Nature Reviews Gastroenterology &Hepatology.

[34]  R. Schwabe,et al.  Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice , 2013, Hepatology.

[35]  C. Tanaka,et al.  An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis , 2013, International journal of experimental pathology.

[36]  S. Friedman,et al.  Fibrosis‐dependent mechanisms of hepatocarcinogenesis , 2012, Hepatology.

[37]  T. Kay,et al.  Macrophage Deletion of SOCS1 Increases Sensitivity to LPS and Palmitic Acid and Results in Systemic Inflammation and Hepatic Insulin Resistance , 2011, Diabetes.

[38]  A. Dalpke,et al.  Suppressor of cytokine signaling 1 (SOCS1) limits NFκB signaling by decreasing p65 stability within the cell nucleus , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Yosuke Osawa,et al.  TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.

[40]  P. Schirmacher,et al.  Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. , 2006, Journal of hepatology.

[41]  Paul J Hertzog,et al.  Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation , 2006, Nature Immunology.

[42]  M. Reiss,et al.  Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. , 2005, Molecular biology of the cell.

[43]  S. Friedman,et al.  Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. , 2005, Journal of hepatology.

[44]  J. Bonner,et al.  Regulation of PDGF and its receptors in fibrotic diseases. , 2004, Cytokine & growth factor reviews.

[45]  Takafumi Yoshida,et al.  SOCS1 Is a Suppressor of Liver Fibrosis and Hepatitis-induced Carcinogenesis , 2004, The Journal of experimental medicine.

[46]  Donald Metcalf,et al.  SOCS3 negatively regulates IL-6 signaling in vivo , 2003, Nature Immunology.

[47]  M. Kubo,et al.  SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. , 2002, Immunity.

[48]  Warren S. Alexander,et al.  Suppressors of cytokine signalling (SOCS) in the immune system , 2002, Nature Reviews Immunology.

[49]  Gennaro Ciliberto,et al.  Increased toxin‐induced liver injury and fibrosis in interleukin‐6–deficient mice , 2000, Hepatology.

[50]  K. Okkenhaug,et al.  Socs1 binds to multiple signalling proteins and suppresses Steel factor‐dependent proliferation , 1999, The EMBO journal.

[51]  C. Trautwein,et al.  Hepatic fibrosis: Concept to treatment. , 2015, Journal of hepatology.